ACADIA Pharmaceuticals - 53 Year Dividend History | ACAD
Historical dividend payout and yield for ACADIA Pharmaceuticals (ACAD) since 1971. The current TTM dividend payout for ACADIA Pharmaceuticals (ACAD) as of April 15, 2024 is $0.00. The current dividend yield for ACADIA Pharmaceuticals as of April 15, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.824B |
$0.726B |
|
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as?dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
